Adverse Events Associated With Treatment for Pan-Susceptible Tuberculosis in San Francisco.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 36322073.
- Also identified by DOI 10.1093/cid/ciac867.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Of 373 patients treated for drug-susceptible tuberculosis, 35.4% (46.2% aged ≥65 years) developed moderate/severe adverse events that required treatment interruption (34.8%), first-line drug discontinuation (26.2%, primarily pyrazinamide), second-line drug initiation (30.0%), and treatment duration up to 3.8 months longer. More safe and effective options are needed, including for the elderly.
Medical subject headings
- Tuberculosis, Multidrug-Resistant
- Tuberculosis